News Cipla Limited

Stocks

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. 07:05:08 2026-08-21 EDT			5-day change	1st Jan Change
1,432.20 ^INR	-0.40%		-1.82%	-5.23%

08-13	Cipla Announces Appointment of Runa Akhtar to Marketing Head, Cipla Urology	CI
08-11	Global drugmakers invest billions to boost US presence	RE

All News

Mentions Relevance

08-13	Cipla Announces Appointment of Runa Akhtar to Marketing Head, Cipla Urology	CI
07-28	Cipla Limited Receives U.S. Fda Approval for Generic Advair Diskus	CI
07-24	Jefferies Adjusts Cipla's Price Target to INR1,170 From INR1,120, Keeps at Underperform	MT
07-23	Cipla Limited, Q1 2027 Earnings Call, Jul 23, 2026
07-23	Cipla Redesignates Global CFO to New Internal Role; Names New CFO	MT
07-23	Cipla Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-23	Cipla Limited Announces Cessation of Sanjay Joseph as Senior Managerial Personnel, Effective July 24, 2026	CI
07-23	Cipla Limited Announces Global Chief Financial Officer Changes	CI
07-23	Cipla Limited Announces Executive Changes	CI
06-24	Avendus Spark Upgrades Cipla to Buy from Add; Price Target is INR1,710	MT
06-16	Cipla Limited Appoints Shivam Puri as Chief Executive Officer of Its One India Business, Effective July 1, 2026	CI
06-11	Cipla's Goa, India Facility Receives VAI Status from US FDA	MT
05-14	Cipla Limited announces Annual dividend, payable on July 25, 2026	CI
05-14	Elara Securities Downgrades Cipla to Reduce from Accumulate; Price Target is INR1,349	MT
05-14	Elara Securities Downgrades Cipla to Sell from Neutral; Price Target is INR1,180	MT
05-14	JM Financial Upgrades Cipla to Buy from Add; Price Target is INR1,546	MT
05-14	Emkay Global Upgrades Cipla to Add from Reduce; Price Target is INR1,450	MT
05-14	Avendus Spark Upgrades Cipla to Add from Reduce; Price Target is INR1,455	MT
05-14	Nirmal Bang Downgrades Cipla to Hold from Buy; Price Target is INR1,404	MT
05-13	Cipla Limited, Q4 2026 Earnings Call, May 13, 2026
05-13	Cipla Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-13	Indian drugmaker Cipla misses Q4 profit view on weak US sales	RE
05-13	Cipla Q4 consol net profit 5.55 billion rupees	RE
05-13	Cipla Limited Appoints Sushrut Kulkarni as President & Global Chief - Integrated Product Development, Effective from May 18, 2026	CI
05-13	Indian drugmaker Cipla's fourth-quarter profit misses view on weak US sales	RE